A B S T R A C T Serum antibodies to exotoxin A and type-specific lipopolysaccharide were measured by passive hemagglutination in 52 patients with Pseudomonas aeruginosa septicemia. Their comparative protective activities were evaluated by relating the titers of each at the onset of bacteremia to subsequent outcome. High acute serum antitoxin and antilipopolysaccharide titers (log2 reciprocal mean titers >5) were associated with survival (76% of 17 with high vs. 46% of 24 with low antitoxin titers, P = 0.05; 85% of 13 with high vs. 48% of29 with low antilipopolysaccharide titers, P = 0.03). In contrast, neither antibody titer was significantly associated (P c 0.05) with patients' age or sex, severity ofunderlying disease, presence ofleukopenia, steroid or immunosuppressive therapy. Despite a correlation between acute titers of the two antibodies (r = 0.33, P = 0.06), they appeared to protect independently and additively. Whereas 75% of 8 patients with high antitoxin titers and only 38% of 16 with low titers survived with low antilipopolysaccharide titers (P = 0.10), 100% (6/6), 73% (8/11), and 38% (6/16) survived, respectively, when both, one, or neither antibody was present in high titer (P = 0.01). Furthermore, the association between high acute serum antitoxin titers and survival was more pronounced in patients with rapidly fatal underlying disease (P = 0.06) and leukopenia (P = 0.12) than in more favorable prognostic and immune categories. These data indicate that serum antibodies to exotoxin A and lipopolysaccharide are found in most patients with P. aeruginosa septicemia
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INTRODUCTION
Pseudomonas aeruginosa (PA)' infections continue to be a life-threatening problem among immunologically compromised hosts in the hospital environment. Under these circumstances PA has the capacity for tissue invasion that often leads to septicemia and death. In most extensive reviews of gram-negative rod bacteremias, PA has been associated with the highest mortality (1). It is not yet clear what components of PA are responsible for its virulence. Lipopolysaccharide (endotoxin) has been implicated as a pathogenic factor. Circulating antibodies to lipopolysaccharide have been shown to prevent or attenuate some of the adverse effects of endotoxin in experimental animals (2, 3) and to act as opsonins, increasing the efficiency of phagocytosis of bacteria by leukocytes (4, 5) . In a study of 182 patients with gram-negative rod bacteremia, including 16 with PA infections (6) , high titers of immunoglobulin (Ig)G antibody to the patient's infecting organism were associated with a significant reduction in the frequency of shock and death. In several instances (but not in any of the PA infections), an examination of sera after absorption with lipopolysaccharide purified from the infecting strain revealed markedly reduced antibody titers. This suggested the specificity of these protection-associated antibodies for endotoxin. Although a number ofattempts to actively or passively immunize animals (7-10) and man (11) (12) (13) (14) against PA endotoxin have met with varying degrees of success, no systematic, quantitative study of antibodies to purified Pseudomonas lipopolysaccharides (ALPS) has been performed in human infections. Specifically, scarce data exist relating ALPS levels in serum at the onset of bacteremic PA infections to subsequent outcome.
Among a number of extracellular enzymes produced by PA, exotoxin A has received considerable recent attention. Widely produced by clinical PA strains regardless of immunotype (15, 16) , it is toxic for tissue cultures (17) (18) (19) (20) and lethal for animals (18, 21, 22) . It has been purified to homogeneity (21, (23) (24) (25) (26) , partially characterized (21, 23, 25) , and its mode of action delineated in cell-free systems (27) (28) (29) . This action, which is identical to that of diphtheria toxin, involves the enzymatic transfer of the ADP-ribosyl moiety from nicotinamide adenine dinucleotide to elongation factor 2, resulting in the inhibition of protein synthesis.
In addition to this demonstrated similarity to diphtheria toxin, there are several other lines of evidence suggesting a possible pathogenic role for exotoxin A. Its in vivo production during human infections is suggested by the demonstration of a systemic antibody response to purified exotoxin (30, 31) . Its protein synthesis-inhibiting enzymatic activity is expressed in vivo during experimental infections in mice (32, 33) . Antitoxin (AT) protects mice against challenge with toxinogenic PA strains, but fails to do so in infections caused by nontoxinogenic organisms (34) . Finally, exotoxin is cytotoxic for human macrophages in vitro (20) , a finding which might help explain its demonstrated interference with bacterial clearance mechanisms in infected mice (34) .
The purpose of this study was to characterize serum antibody responses to exotoxin A and lipopolysaccharide in patients with bacteremic PA infections and to assess the relation between antibody titers to each at the onset of bacteremia and subsequent outcome. By studying the protective activities of their respective antibodies, we hoped to better define the pathogenic roles of exotoxin and endotoxin in serious PA infections.
METHODS
Patient selection and clinical criteria. Selected for study were a consecutive series of 52 patients, 65% of whom were male, with an average age of 54 yr (range 12-89 yr), hospitalized on the medical, surgical, or gynecological services at the University of California Medical Center between 1 (30) .
Passive hemagglutination assay for AT (PHA-AT assay). Fresh sheep erythrocytes (SRBC) were sensitized using chromic chloride and coated with toxin (31) . Uncoated cells were prepared in the same manner except that toxin was deleted from the sensitizing mixture. Serum samples were heat-inactivated, absorbed with uncoated SRBC, serially diluted, and assayed in microtitration plates using sensitized toxin-coated or uncoated SRBC as previously described (31) . PHA-AT titers began with a dilution of 1:2. Titers were expressed as log2 oftheir reciprocals, and for statistical purposes, titers < 1 were considered to be 0. A positive reference serum (31), negative serum control, buffer controls without serum, and uncoated SRBC with test serum were included in each assay. Acute and convalescent specimens from each patient were assayed simultaneously.
Passive hemagglutination assay for ALPS (PHA-ALPS assay). Serum antibodies to lipopolysaccharides of the seven Fisher-Devlin-Gnabasik PA immunotypes (38) were assayed by a modification of a published method (39) . Fresh SRBC were washed three times in normal saline and resuspended at a concentration of 10% (vol/vol) in phosphatebuffered saline, pH 7.2.'This cell suspension was mixed with an equal volume of purified immunotype-specific PA lipopolysaccharide (37) (supplied by M. Fisher, Parke, Davis & Co.) at a final concentration of 50 ,ug/ml in phosphate-buffered saline and the mixture incubated at 37°C for 30 min. SRBC were then washed three times in normal saline and resuspended at a concentration of 1% (vol/vol) in normal saline plus 1% bovine serum albumin. Uncoated control cells were prepared in similar fashion except that lipopolysaccharide antigen was deleted from the coating mixture. Serum samples were heat-inactivated at 56°C for 30 min, and twofold dilutions performed in normal saline plus 1% bovine serum albumin in microtitration plates. Duplicate serum aliquots were incubated overnight at room temperature with an equal volume of 0.2 M 2-mercaptoethanol (2ME) in normal saline before dilution and
assay. An equal 50-IAI vol of lipopolysaccharide-coated SRBC, representing the immunotype of the patient's blood isolate, was then added to each dilution well, the plates agitated and allowed to stand at room temperature for 4 h before reading for PHA. PHA-ALPS tests performed on sera before 2ME treatment (total immunoglobulin) began with a dilution of 1:2, and those done on sera treated with 2ME (IgG) began with a dilution of 1:4. Titers were expressed as log2 of their reciprocals and, for statistical purposes, total immunoglobulin titers <1 and IgG titers <2 were considered to be 0 and 1, respectively. A human hyperimmune, heptavalent reference serum (PEU 26 of 15 August 1969) was included with each assay, and acute and convalescent samples from each patient run simultaneously. PHA-ALPS determinations on 52 healthy subjects were performed by M. Fisher (Parke, Davis & Co.). The assay method used was identical to that described above for ALPS determination on patient samples, and the titers obtained by both laboratories on the reference serum were within one dilution of each other for all seven immunotypes.
Culture preparation and assay for toxin. Several isolated colonies of patients' PA blood isolates grown overnight on blood agar plates were transferred to trypticase soy agar slants, and grown again overnight at 32°C. Growth from these slants was suspended in TSBD plus 10% glycerine, and frozen in small aliquots at -700C until further use. Before assay, cultures w'ere thawed, inoculated on trypticase soy agar slants, and overnight growth at 320C suspended in 60 ml of TSBD plus 5 mM nitrilotriacetic acid in 300 ml baffled nephelometer flasks. These cultures were grown for 18 h at 32°C in a rotary shaking incubator at 250 rpm (Psychrotherm, New Brunswidk Scientific Co., Inc., New Brunswick, N. J.), centrifuged at 10,000 g for 30 min in the cold, and the supemates filtersterilized.
Toxin was measured by hemagglutination inhibition (HI) (26) , employing the microtiter PHA-AT system described above. Four hemagglutinating units of sheep AT serum in 25 ul of veronal-buffered saline plus bovine serum albumin were inc'ubated at 37°C for 1 h with twofold dilutions of unconcentrated culture filtrates in an equal volume of buffer. Toxin-coated SRBC were then added to microtitration wells, hemagglutination read after 4 h, and HI end points related to a simultaneously run toxin standard.
Statistical analyses. The significance of differences in survival between groups of patients with high and low antibody titers was determined with a one-tailed Fisher exact test. Linear regression analysis was performed by the method of least squares, and the validity of fit determined by the correlation coefficient r. The significance of r was computed by a two-tailed Student's t test using the statistic t = r/Vni-2/ /1--2 Mean antibody titers were compared using a twotailed Student's t test. The incidence in high and low antibody groups of various prognostic categories, leukopenia, steroid therapy, and administration of cytotoxic drugs was compared using a two-tailed Fisher exact test. Most computations were performed on a programmable calculator using available software (model 65, Hewlett-Packard Co., Palo Alto, Calif.).
RESULTS
Primary sites of infection among the 52 patients studied were the urinary tract in 12, the gastrointestinal tract in 8 (perirectal abscess or oropharyngeal abscess), the lung in 7, the skin in 2, and the pelvic organs in 1. (Fig. 1) . The mean AT titer of this group (expressed as log2 of reciprocal titer) was 5.8 (+3.3 SD). AT was present in 23 of 24 convalescent sera from patients who survived bacteremia caused by toxinogenic strains, and the mean titer was 9.1 (±5.0 SD). 11 ofthese patients (46%) demonstrated fourfold or greater titer rises, and 3 showed twofold rises. In contrast, the mean acute AT titer of nine patients infected with nontoxinogenic PA strains was 2.9 (+2.2 SD), with no increase in individual titers or in mean convalescent titer (2.5+3.1 SD) among four survivors. Whereas 72% of 100 healthy blood donors had detectable serum AT (Fig. 1) , most titers were low, and the mean titer of 2.6 (+2.2 SD) was significantly lower than either the mean acute (P = 0.001) or convalescent (P < 0.001) titers of the bacteremic patients. The correlation between both acute and convalescent AT titers and in vitro toxin production by infecting strains, as measured by HI (Fig. 2) , was further indication that in vivo toxin release bore a direct relationship to toxin measured in vitro.
PHA-ALPS to infecting PA strains was detectable (log2 of reciprocal titers 21) in all 42 acute and 25 convalescent sera from patients who survived their bacteremias (Fig. 3) ; mean acute and convalescent antibody titers were 4.6 (+2.5 SD) and 7.0 (+2.8 SD), Incubation of sera with 2ME resulted in in PHA-ALPS titers consistent with the noted disproportionate contribution by IgN in the assay system (14) . The mean acute of bacteremic patients was reduced by th from 4.6 (±2.5 SD) to 3.1 (+1.6 SD), an convalescent titer from 7.0 (±2.8 SD) to 4.' However, the correlation between ALPS and after treatment with 2ME was excel case of acute titers, r was 0.55 (P = 0.04 convalescent titers r was 0.61 (P = 0.001) this close correlation, only ALPS titers -98% of sera serum samples were subsequently analyzed, except as ding on im-noted. In of types 2 As shown in Fig. 4 , the correlation between total r than either ALPS and AT titers at the onset of bacteremia was tatients. 6 of not close (r = 0.33, P = 0.06). However, when 2ME-as for whom treated sera were substituted in the PHA-ALPS assay, Id or greater the correlation improved (r = 0.50, P = 0.003). This is, 8 showed observation could perhaps be explained by the previemonstrated ous demonstration that the PHA-AT assay measures predominantly IgG antibodies (29) , and thus by excluda reduction ing the IgM component of PHA-ALPS with 2ME, the previously two assays are made more comparable.
A antibodies
To evaluate the possible protective activities of AT ALPS titer and ALPS, we looked for an association between the is treatment titers of each at the time of onset of bacteremia and id the mean subsequent survival. In relating AT and survival, 9 of 5 (+2.4 SD). 52 patients whose infecting strains were nontoxinotiters before genic in vitro were excluded from analysis, and 2 pa-[lent; in the tients were eliminated from the analysis of ALPS 02), and for and outcome because their infecting strains were not I . In view of available for immunotyping. Five additional patients )f untreated were excluded because their PA isolates were nontypable, and two were eliminated because of inadequate serum samples. Thus, the analysis of AT and survival considered 41 patients, the analysis of ALPS included 42 patients, and a combined analysis involved 33 patients. * Individual AT titers of patients who survived and those who succumbed to their PA bacteremias are plotted separately in Fig. 5 . Titers varied over a wide range in both groups and although the mean acute titer of those who survived (6.2+3.7 SD) was somewhat . * higher than the mean titer of those who succumbed (5.2±2.6 SD), the difference was not significant (P = 0.36). However, when patients were separated into low-and high-titered groups (titers '5 and >5) (Table  II) , survival was clearly greater among those with high AT titers (P = 0.05). As indicated in Table III (Table IV) , there was an indication of protection associated with high titers in the more severe prognostic categories, particularly among those CONVALESCENT patients with rapidly fatal underlying diseases (P PS titers to in-= 0.06). Likewise, as shown in Table V , there was a trend mia compared toward enhanced survival among patients with high atter supplied AT titers whether or not they were leukopenic (P erum samples = 0.12 and P = 0.23, respectively).
ive blood cul-
The data relating survival to ALPS titer were similar from survivorsto those for AT, but with some important differences. before treatment with 2ME (total ALPS) and (B) after 2ME treatment (ALPS-IgG), plotted against AT titers of the same specimens.
among those who survived compared with those who died (mean = 3.4+ 1.9 SD, P = 0.005) (Fig. 6) . As in the case of AT, patients with high ALPS titers (>5) at the time of their initial positive blood cultures had a higher survival rate than those with low titers (P = 0.03) (Table II) . However, although not at a statistically significant level, there was a greater disparity in respect to certain host factors between the high-and low-titered groups, including prognostic category, presence of leukopenia, and prior steroid administration, than had been the case with AT (Table III) . Despite these findings, there was a trend toward heightened survival in association with high ALPS titers in all three prognostic categories (Table IV) . In contrast to AT, there was a stronger association between high ALPS titers and survival among nonleukopenic patients (P = 0.08) than among those with low leukocyte counts (P = 0.40) (Table V) .
Two trends emerged when acute AT and ALPS titers of33 patients infected with typable, toxinogenic strains Antibodies to Exotoxin and Lipopolysaccharide in Pseudomonas Sepsis were analyzed together (Table VI) . First, there was a strong association between high AT titers (>5) and subsequent survival, even when the ALPS titers were low ('5); and conversely, more favorable survival rates were found among patients with high ALPS titers (>5) irrespective of AT titer. Second, the apparent protective activities of AT and ALPS appeared to be at least additive in that all six patients survived who had high titers of both antibodies at the time ofbacteremia. Conversely, the greatest mortality (10 of 16) was observed when both types of antibody were present in low titer and an intermediate mortality rate (3 of 11) occurred when one or the other but not both were found in high titer.
DISCUSSION
Our data confirm that a majority of normal adults have serum antibodies to exotoxin A and one or more of the lipopolysaccharide, immunotype-specific antigens ofPA. Significant antibody responses to both commonly accompanied bacteremic infections, even with rapidly fatal underlying disease, leukopenia, and steroid or immunosuppressive drug therapy. Mean acute and convalescent AT titers were higher and titer rises more pronounced among surviving patients with these adverse host factors than among those lacking them (data not shown). In contrast, acute and convalescent ALPS titers were generally lower among patients in these categories, and titer rises less common. The demonstration of rising AT titers confirmed our earlier data suggesting that exotoxin is produced in vivo during human infections and induces an antibody response (30, 31) . Further, there was a direct relation between the amount of exotoxin produced by blood isolates in vitro and the titer of AT present in patients' sera. That this correlation occurred with acute AT titers suggested antecedent exposure of patients to their infecting organisms. This was most likely due to colonization, particularly of the gastrointestinal tract, before bloodstream invasion (40) . AT synthesis might have increased through an anamnestic response in patients with preexisting antibodies. An alternative explanation for high acute AT and ALPS titers is the possibility that infection, or even bacteremia, which may have antedated initial blood cultures, was not promptly recognized.
Because AT and ALPS titers were obtained simultaneously with initial blood cultures positive for PA, we were able to assess the humoral component of host defenses at the onset of bacteremia. Survival after bacteremia was significantly associated with both high Further confirmation that the observed association between high antibody titers and survival was independent of other host factors was obtained by analyzing subgroups of patients defined on the basis of two of the most critical host factors: severity of underlying disease and total leukocyte counts. In the case of AT, despite small numbers, the association between high antibody titers and survival was stronger, if anything, among patients with rapidly fatal underlying disease compared with less ill patients. Likewise, high AT titers apparently represented an equal or greater survival factor for leukopenic compared with nonleukopenic patients. In similar fashion, the association between high ALPS titers and survival applied more or less equally to patients in all three McCabe-Jackson prognostic categories. However, in contrast to AT, there was greater survival with high ALPS titers in nonleukopenic patients. This result is not surprising in view of the relationship between ALPS titers and heat-stable opsonizing antibodies against PA and the expectation that opsonization requires functioning phagocytic cells. (41) .
These data suggest that in the face of negative host factors, such as inadequate numbers of circulating leukocytes or severe underlying disease, serum antibodies to exotoxin and lipopolysaccharide may assume critical importance. Further, the independent and additive protective activities of the two antibodies suggest separate mechanisms of protection.
The protective effects of active or passive immunization with Pseudomonas lipopolysaccharide or ALPS in experimental animal infections are well documented (7) (8) (9) . However, the clinical efficacy of such immunizations in man is less clear (12) (13) (14) Such patients may have initially produced antibodies after immunization, but titers subsequently declined in the face of continued immunosuppression (14) . In the case ofexotoxin A, passive protection by highly specific AT serum has been demonstrated in experimental mouse burn infections (34) . Accompanying this protection were significantly lower levels of bacteremia compared with similarly infected, untreated control animals (34) . Furthermore, passive immunization with AT prevented enzymatic inhibition ofprotein synthesis, presumably resulting from in vivo toxin release, which occurred in the tissues of unimmunized mice infected with toxinogenic PA strains (33) . These data derived from experimentally infected animals complement the human serological data presented here in suggesting a significant pathogenic role for exotoxin A as well as the potential clinical efficacy of immunization against it.
Our data indicate that AT and ALPS are present early in the serum of most patients with PA septicemia, increase with survival, and are protective. This suggests that antibodies passively provided or actively engendered to both exotoxin and lipopolysaccharide may have therapeutic or prophylactic potential.
